Introduction

Inflammation is a natural protective mechanism that resolves infections and injuries of the target tissue.1 Failure to effectively resolve the inflammation and return the affected tissue to homeostasis leads to maladaptation and precipitation of pathophysiologic consequences that often result in the development of chronic maladies, including cardiovascular diseases and diabetic complications.2,3 It has been well established that injury-elicted inflammation in the vasculature often causes excessive proliferation of vascular smooth muscle cells within vessel walls and the subsequent expansion of the intima, leading to the eventual blockage of the vessel.4–6 These remodeling processes are intensified especially in patients with diabetes. Although effective in combating neointima hyperplasia, current anti-inflammatory and antimitotic drugs often display significant side effects and toxicity that deem systemic applications unfeasible, and their local delivery is achieved via drug-eluting stents.7,8 Therapeutic reagents that can be administered systemically stand the benefit of providing alternative avenues for treating acute vascular injuries as well as circumventing overall chronic inflammation in the vasculature.9

RAGE is a pattern recognition receptor that recognizes multiple endogenous ligands and triggers innate and adaptive immune responses.10–14 Signaling via RAGE has been associated with vascular inflammation and implicated in the development of cardiovascular diseases.15,16 Prior studies17,18 have shown that administration of sRAGE can protect against injury-mediated vascular inflammation and neointimal expansion by functioning as a RAGE decoy. Such protection by sRAGE may also be extended to other inflammatory conditions, including diabetic complications and atherosclerosis.19,20 Our recent study21 demonstrated that N-glycoform modifications of sRAGE modulate its bioactivity: compared with sRAGE produced in insect Sf9 cells used in previous...
studies (ie, 5 μg/g body weight, daily injection for a week), a single, low dose of sRAGE produced in Chinese hamster ovary cells (sRAGECHO) (ie, 3 ng/g body weight) can substantially reduce neointima growth and inflammation in a rat carotid balloon injury model. These findings render sRAGECHO an attractive therapeutic candidate with clinical potential.21,22

Although previous studies assessed how sRAGE treatment affected neointima growth via histomorphologic analyses of postmortem vessel sections,17,18,21 direct assessment of sRAGE action in vivo has not been performed. Vessel ultrasound sonography is a technique that can be used noninvasively in clinical practice to monitor arterial structure and function.23–25 To further validate sRAGE efficacy to suppress neointima growth, and to provide a basis for future clinical applications, we performed sonograph studies on carotid balloon denudation-injured rats before histology and compared these results with those observed in histomorphologic analyses. Such studies render an independent assessment of sRAGECHO efficacy in vivo, and can validate its potential as a candidate therapeutic protein for treating vascular injury and inflammation. The present study was an extension of our previously published work.21

Materials and Methods

Subjects

Male Wistar rats (400–450 g) were purchased from Charles River Laboratories (Wilmington, Massachusetts) and maintained in a vivarium fed the National Institute on Aging on ad libitum food diet (NIH-07 mouse/rat diet; National Institutes of Health, Bethesda, MD) with access to filtered water. Each study group contained 6 to 15 rats.

Carotid artery balloon denudation injury procedure

The surgical procedure and post surgery care have been described in detail,21 and have been in compliance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals (NIH publication No. 3040-2, revised 1999), and with the institutional Animal Care and Use Committee approved protocol.

Production and administration of sRAGE

Immediately following the surgery, rats were administered the designated dose of sRAGE via intraperitoneal injection. Generation of sRAGECHO, sRAGECHO, and sRAGECHO(N25T/N81T) expression vectors, as well as purification of sRAGE recombinant protein have been described in detail.21

Vessel ultrasound sonography

Vessel ultrasound sonography was conducted on the 0 Day (ie, surgery day, before surgery), and on the seventh and 14th day postsurgery. Rats were sedated with isoflurane (2% in oxygen) via facemasks, and put in the supine position. After shaving frontal neck skin hair, a 40 MHz probe was used to scan the carotid arteries. An M-mode tracing was recorded at 3 points in the long-axis view: 3 and 10 mm distal to the base, and 2 mm proximal to the bifurcation. Each M-mode tracing included the whole vessel wall thickness and lumen diameter. Vessel wall thickness was also recorded alone, using a zoom-in function. A B-mode scan was recorded at 2 mm proximal to the bifurcation. Each vessel was measured 5 times. The vessel wall thickness and lumen diameter at minimal and maximal points were measured using National Institutes of Health Image J software. The parameters from the non-operated right carotid artery of the same rat were used as control.

Tissue collection and histomorphologic analysis

Isolation of carotid vessels and histomorphologic analyses have been described.21 In all analyses, parameters from the nonoperated right side of the carotid artery of the same subjects were used as the normal control relative to the balloon-injured left side of the carotid artery.

Allocation concealment

Allocation concealment was applied to balloon denudation surgery, sonographic studies, and histomorphologic analyses. Investigators involved in the procedure were also blinded in respect to sRAGE types and dose administered.

Statistical analysis

Numerical data are expressed as means (SEM). Sonographic data were analyzed with multisample comparison ANOVA with post hoc Bonferroni corrections. A value of P < 0.05 was considered statistically significant.

Results

Beneficial effects of sRAGECHO treatment measured by vessel ultrasound sonography 1 to 2 weeks after the injury

Our previous studies21 had demonstrated that administration of sRAGE immediately after arterial injury is most therapeutically effective. To monitor sRAGECHO effects in live rats with carotid arterial injury, we performed the ultrasound sonography procedure on rats before the surgery, and at 1 and 2 weeks postsurgery. Although at 1 week postsurgery the maximal vessel lumen diameter of injured vessels treated by sRAGECHO is clearly distinguishable from that of placebo-treated vessels (Figure 1A), the measurement of average vessel wall thickness of these 2 groups was not clearly differentiated until 2 weeks postsurgery (Figure 1B), suggesting that sufficient time (ie, at least 1 week) is required to assess the benefits of sRAGECHO treatment in a live animal model.

Correlation of ultrasound sonography and histomorphologic analyses

To test the correlation of sonographic data with that obtained from postmortem histologic measurement, we plotted the data from the 2 independent measurements, using the lowest effective dose (ie, 0.5 ng/g body weight). Despite the shrinkage of vessel cross-sections during the histologic process, reasonably high correlations between the data from the 2 measurements were apparent in the scatter plots (lumen diameter: R = 0.72; vessel wall thickness: R = 0.76) (Figure 2A and 2B), suggesting that the effect of sRAGECHO treatment can be independently, and perhaps reliably monitored in vivo (Figure 2C).

Vessel sonographic assessment in rats treated with different sRAGE doses and sRAGE produced from different cells

On the basis of timing and correlation with histologic results shown in Figures 1 and 2, we also measured lumen diameter and vessel wall thickness at 2 weeks postsurgery in rats treated with sRAGECHO at lower (0.5–1.5 ng/g body weight) (Figure 3A and 3B) and higher doses (1.5–6 ng/g body weight) (Figure 3C and 3D). When vessel wall thickness was measured, 1.5 ng/g and higher doses of sRAGECHO treatment appeared to be statistically similar to those of nonoperated vessels (Figure 3A and 3C). However when lumen diameter was measured, dose-dependent improvement in
groups treated with 0.5 to 3 ng/g sRAGE CHO was detected (Figure 3B and 3D), suggesting that the latter parameter may be more sensitive.

Our previous work\textsuperscript{21} showed that specific N-glycoform modifications are a key determinant of sRAGE bioactivity, and that not only N-glycosylation, but also mammalian cell-specific,

---

**Figure 1.** Observation of soluble receptor for advanced glycation end products (sRAGE) effects using vessel ultrasound sonography during 2 weeks of postarterial injury. (A) Maximal lumen diameter during the 2 weeks postinjury. (B) The average vessel wall thickness during the 2 weeks postinjury. Empty circle = nonoperated; filled square = balloon-injured and sRAGE-treated; empty square = balloon-injured and placebo-treated. Values are means (SEM); sRAGE administered = 0.5 ng/g body weight. a = \( P < 0.05 \) sRAGE Chinese hamster ovary-treated samples versus nonoperated; b = \( P < 0.05 \) sRAGE Chinese hamster ovary-treated samples versus placebo-treated samples.

**Figure 2.** Correlation of ultrasound sonography and histology in soluble receptor for advanced glycation end products (sRAGE) (0.5 ng/g) treated carotid vessels shown in scatter plot of data from (A) lumen diameter and (B) vessel wall thickness at 2 weeks postinjury (nonoperated, injured with sRAGE, and placebo-treated, \( n = 12 \) of each group). (C) Representative sonographic and histologic (100 ×) images.
complex-type N-glycosylation is critical for the observed high therapeutic efficacy of sRAGE. Independent assessment using sonography (Figure 4) with an established optimal dose of sRAGECHO further confirmed a significantly higher efficacy of sRAGECHO relative to that of nonglycosylated sRAGE (N25T/N81T) and sRAGE produced in insect Sf9 cells.

Discussion

The therapeutic value of sRAGE has been well recognized and tested in various animal models, including arterial injury models. Administration of sRAGE, a decoy of RAGE, can reduce injury-associated, RAGE signal-mediated chronic inflammation and minimize maladaptation and remodeling in vasculature, thus decreasing the risk of cardiovascular diseases and other vessel-associated complications. Although previous studies discovered that sRAGE can be used to block neointimal growth and formation of atherosclerotic plaques in animal models, to achieve the blockage, a high dose and multiple administrations of sRAGE produced in insect Sf9 cells were employed. Our recent study demonstrated that specific N-glycoform modifications are the key determinant underlying sRAGE bioactivity and therapeutic efficacy: a low, single dose of sRAGE produced in CHO cells can significantly reduce injury-associated inflammation and neointimal growth. In addition to the observed low efficacy, glycoforms from insect cells are also immunogenic in mammals, and therapeutic glycoproteins must be produced from mammalian sources. Previous studies, including ours, had evaluated therapeutic effects of sRAGE mainly based on postmortem histomorphologic analyses of the vessel cross-sections and in vitro bioactivity assays. Although these assessments, especially histologic studies,
provided important and direct information of the vessel condition, including inflammation and formation of the neointima, these approaches cannot be used for clinical evaluation of treatment.

The present study demonstrates that injury of the vessel as well as the therapeutic effects of sRAGECHO can be independently evaluated via vessel sonographic assessment. Similar to the results obtained from histology shown in our previous study,21 current sonographic studies also showed a degree of dose-dependent attenuation of vessel lumen diameter, although this was less apparent in measured vessel wall thickness (Figure 3). Consistent with histology,21 sonography also showed that paucimannose-glycan modified sRAGESf and the non-glycosylated sRAGECHO(N25T/N81T) were ineffective when used in the same dose (3 ng/g) as sRAGECHO (Figure 4). Previous studies17,21 showed that sRAGECHO administered immediately after arterial injury was most effective to restrict neointimal expansion. The manifested beneficial effects of sRAGECHO are not readily detectable in vivo until at least 1 week after surgery and treatment, and the therapeutic outcome becomes apparent 2 weeks after surgery and treatment (Figure 1). These observations suggest that blocking RAGE alarmin ligands immediately after injury circumvents RAGE-mediated inflammatory signaling, and allows the injured vessel to undergo a repair process with less, or controlled, inflammation leading to a healing course with reduced remodeling. Compared with our previously published histology results,21 vessel ultrasound sonography appears to be less sensitive to discern the difference between nonoperated vessels and vessels operated on with treatment when a higher dose of sRAGECHO (3 ng/g) was used (Figure 4A), whereas such difference was discernable by histology. When a lower dose of sRAGECHO was used (0.5 ng/g), the difference between treated and nonoperated vessels is clearly discernable and there was a better correlation between sonography and histology (Figure 2). This is likely due to the fact that 0.5 ng/g is not an optimal dose, and that remodeling of the vessel wall by balloon denudation was not suppressed as much as that in a situation when a higher dose was administered. These observations suggest that sonographic data should serve as a reference for application, and that the exaggerated benefits observed in higher sRAGE doses should be taken into consideration to determine a proper dose for the best treatment outcome.

Conclusions

Our research using vessel sonography to monitor sRAGE effects in live rats reaffirmed that specific N-glycoform-modified sRAGE, produced in CHO cells is highly effective in vivo to attenuate neointimal growth after arterial injury, compared with that produced in insect cells. This in vivo approach also provides a basis for monitoring sRAGE effects in future clinical applications.

Acknowledgments

This work was supported by the intramural research program of the National Institute on Aging, National Institutes of Health (Hyun-Jin Tae, Natalia Petrashevskaya, Ismayil Ahmet, Mark L. Talan, Edward G. Lakatta, and Li Lin), by a Priority Research Centers Program grant from the National Research Foundation ( NRF-2009-0093812 ) funded by the Ministry of Science, Information and Communication Technology, & Future Planning in the Republic of Korea (Hyun-Jin Tae), and by a Korea Research Foundation grant ( KRF-2009-013-E00008 ) (Sungha Park). Li Lin, Natalia Petrashevskaya, Ismayil Ahmet, Hyun-Jin Tae, and Markl. Talan designed the studies; Hyun-Jin Tae, Natalia Petrashevskaya, Ismayil Ahmet, Sungha Park performed the studies; Natalia Petrashevskaya, Ismayil Ahmet, Hyun-Jin Tae, Markl. Talan, Li Lin and EdwardG. Lakatta interpreted data; Li Lin and Ismayil Ahmet wrote the manuscript. The authors thank Wen Wei for purification of recombinant sRAGE.

Conflicts of Interests

The authors have indicated that they have no conflicts of interest regarding the content of this article.

References

[1] Olin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol. 2012;22: R73–R80.
[2] Kotani H, Sugiyama M, Iwaya Y, Tsuchihashi H. The role of RAGE in atherosclerosis. Biochem Pharmacol. 2009;78:319–325.
[3] Xu CB, Sun Y, Edvinsson L. Cardiovascular risk factors regulate the expression of vascular endothelin receptors. Pharmacol Ther. 2010;127:148–155.
[4] Ma X, Oyamada S, Gao F, Wu T, Robich MP, Wu H, Wang X, Buchholz B, McCarthy S, Gu Z, Bianchi FT, Selik DR, Laham R. Pdctaxel[]sirulimus combination coated drug-eluting stent: in vitro and in vivo drug release studies. J Pharm Biomed Anal. 2010;54:807–811.
[5] Slavin L, Chhabra A, Tobias JM. Drug-eluting stents: preventing restenosis. Cardiol Rev. 2007;15:1–5.
[6] Lank Tae, Hyun-Jin Tae, Shin CY. RAGE and cardiovascular disease. Front Biosci. 2011;16:486–497.
[7] Chavakis T, Biere A, Al-Fakheri N, Schneider D, Witte S, Tinti N, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507–1515.
[8] Chen Y, Akiraw EM, Chen W, Henegar AU, Moser B, Desai D, Shen JM, Webster KC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Naka Y. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008;181:4272–4278.
[9] Lin L. RAGE on the Toll Road? Cell Mol Immunol. 2006;3:351–358.
[10] Lin L, Tae HJ, Lakatta EG. The Glycoform Modifications of sRAGE Matter. Cardiol Pharmcol. 2013;2:e114.
[11] Neeper M, Schmidt AM, Brent J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–15004.
[12] Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci. 2009;14:1403–1413.
[13] Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2012;106:842–853.
[14] Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liu H, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959–972.
[15] Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Foroud F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, Topol EJ. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 2003;107:2238–2243.
[16] Buccherelli LG, Wendt D, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kiskinger T, Lee DC, Kashyp Y, Schmidt AM, Abrams CH, Brown AT, Moursi MM. The effects of acarbose combination coated drug-eluting stent: in vitro and in vivo drug release studies. J Pharm Biomed Anal. 2002;106:2827–2835.
[17] Tae HJ, Kim JM, Park S, Tomiya N, Li G, Wei W, Petrashevskaya N, Ahmet I, Pang J, Cruschitz S, Riebe RA, Zhang Y, Morrell CH, Browe D, Lee YC, Xiao RP, Talan MI, Lakatta EG, Lin L. The N-glycoloyfom of sRAGE is the key determinant for its suppressive effect on accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[18] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[19] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[20] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[21] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[22] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[23] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[24] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[25] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
[26] Miyazaki T, Kamei E, Naka Y, Lieberman M, Tae HJ, Lakatta EG, Lin L. The N-glycoform of sRAGE is the key determinant for its suppression of accelerated diabetic atherosclerosis. Atherosclerosis. 2008;199:310–316.
H.-J. Tae et al. / Current Therapeutic Research 76 (2014) 110–115

[26] Harja E, Bu DX, Hudson BJ, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008;118:183–194.

[27] Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hammerling GG, Nawroth PP, Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113:1641–1650.